Private Equity

Private equity bids long goodbye to IPOs

13 Dec 2024

Buyout firms called $130 bln more from fund investors than they handed back between 2022 and early 2024, piling on pressure to return capital. Public markets are an increasingly impractical way to sell large investments quickly. Creative finance commands an ever greater premium.

ESR take-private throws up Asia exit quandary

13 Dec 2024

A group led by US investors offered to privatise the Asian real estate fund manager for $7 bln. Hong Kong's dismal market and ESR's complex business merits the move, yet backers will find it hard to re-list. Asia offers slim pickings for regional groups with IPO dreams.

Walgreens invites a Rube Goldberg buyout plan

12 Dec 2024

The flailing $8 bln drugstore would be a cheap target were it not for a $36 bln morass of debt, long-term leases and opioid liabilities. Yet a ruthless buyer could lean on cutting rents, chairman Stefano Pessina’s 17% stake and sellable bits to excavate whatever is left to save.

Buyout barons’ Europe bargain hunt will intensify

11 Dec 2024

Preqin data shows that funds focusing on the region are outperforming North American ones, helped in part by a 10% valuation discount on local deals. The gap may grow as US stocks get more expensive. But for Europe it’s a sign of corporate weakness, rather than strength.

A $13 bln cash sale breaks buyout doom loop

9 Dec 2024

In a tough market for M&A and IPOs, private equity shops have been recycling assets to sate anxious investors. GTCR’s deal to offload its insurance broker to Arthur J. Gallagher provides a sign that the tide may be turning. Whether animal spirits will persist is the question.

Japan’s virtuous M&A circle starts with 7-Eleven

5 Dec 2024

The battle for control of $45 bln convenience store owner Seven & i is being cheered in Tokyo. It’s evidence of progress in the drive to improve efficiencies in the world’s third-largest economy. It could also be a sign of what’s to come if officials make the right next moves.

Bain’s Japan chip IPO is a tough sell

3 Dec 2024

The US private equity firm will list Kioxia six years after leading the memory unit's $18 bln carve-out from Toshiba. The roughly $5 bln equity valuation means poor returns for sellers. And convincing new investors to look past Kioxia's crippling debt pile will be a slog.

Buyout barons salivate over uncertain wealth prize

20 Nov 2024

Blackstone says $80 trln is up for grabs from coaxing individual investors into private-market assets. KKR puts the figure at $200 trln. The range reflects the variety of people whose nest eggs the firms are targeting, and regulatory hurdles. Shareholders aren’t counting on it.

Singapore’s banking giant DBS is coming of age

12 Nov 2024

The $90 bln Singapore lender will start returning capital to shareholders through share buybacks. Incoming CEO Tan Su Shan will retain sufficient firepower to pursue bold M&A, though changing US policy in its Asian backyard may merit a cautious turn.

Rubber meets road for divergent buyout-shop models

7 Nov 2024

Strong quarterly results and the US election lifted enthusiasm for Apollo, Blackstone, Carlyle and KKR. After pursuing different paths to gather nearly $3 trln of combined assets, however, their opportunities and risks vary. Those leveraged to insurance are under fresh pressure.

German M&A flurry is powered by lasting tailwinds

4 Nov 2024

Teutonic deal volumes are below their 2021 peak, like everywhere else. Yet a burst of activity, including the $15 bln privatisation of DB Schenker and $16 bln Covestro sale, show signs of life. Radical changes to the country’s industrial model imply an enduring rebound.

China pins stimulus on money merry-go-round

23 Oct 2024

Beijing plans to swap some of its $9 trln of local government debt into bonds with full, rather than implicit, state backing. The rejig will lower rates of interest, lengthen maturities and allow provinces to issue more debt to banks. That will juice spending for a while.

EQT defers exit brainteaser with school deal

22 Oct 2024

Swedish firm EQT is reinvesting in education group Nord Anglia alongside Neuberger Berman for $14.5 bln, instead of a sale or listing. It highlights how buyout groups are keeping assets for longer. In this case, that comes with rising regulatory risks, and limited exit options.

Growth-hungry EQT boss faces an M&A puzzle

17 Oct 2024

The $40 bln buyout group’s CEO Christian Sinding is practically shouting from the rooftops that he wants to buy a private-markets peer. So-called secondaries targets, the biggest of which is Ardian, make sense. But it’s a sellers’ market and EQT’s Swedish stock may be a turnoff.

Measured UK tax hike can avoid dealmakers’ Brexit

16 Oct 2024

Chancellor Rachel Reeves has to raise money in her Oct. 30 Budget and may up capital gains tax from 28% to 35%. That would require 2,000 buyout barons to pay $120,000 extra on their funds’ profits. Such a small hit would probably stave off a threatened private equity exodus.

Fiery family feud is opportunity for Korea Inc

16 Oct 2024

Watchdogs are looking into a messy takeover battle between $12 bln Korea Zinc's founding houses. One has teamed up with Bain, the other with Asian fund MBK. Each is decrying its rival's tactics. The saga throws a timely spotlight on the country's governance shortcomings.

CD&R $17 bln French deal may hinge on big retreat

15 Oct 2024

Paris is concerned about the future of critical medicines if the private equity firm buys a stake in Sanofi’s consumer unit. CD&R can promise bigger investment and still get a decent return. Giving up control by bringing in a Gallic co-investor might also soothe the government.

Direct lenders’ golden moment is over

10 Oct 2024

The core of private credit that’s focused on buyout debt surged after the pandemic, spurring the industry to $850 bln in assets. Yet with public markets roaring, returns will fall. Rather than replacing Wall Street banks, private players like Ares will have to cooperate instead.

Sanofi sale is critical health check for mega LBOs

10 Oct 2024

The French pharma company is deciding whether to sell its consumer drugs unit to Clayton Dubilier & Rice or PAI for $17 bln, says Bloomberg. It helps that volatile equity markets make an alternative listing riskier. A successful deal could give large buyouts a shot in the arm.

Debt feast helps buyout firms through IPO gloom

7 Oct 2024

Dividend recaps, where private equity managers pile debt onto a company to give themselves a payday, are booming, with $17 bln in the US last month. Since public offerings look tough, it’s a handy cash-raising alternative. The trend will continue, if the economy plays ball.